UPDATE 1-Hologic posts Q2 net loss, shares down on product delay

* Q2 net loss $8.97/shr vs. profit of $0.22/shr yr-ago

* Q2 revenue down 6.7 percent to $402.0 mln

* Sees delay in U.S. launch of Tomosynthesis system

* Shares down 15 percent after the bell

May 4 (Reuters) - Medical diagnostics company Hologic Inc (HOLX.O) posted a second-quarter loss and said it sees a delay in the U.S. launch of its Tomosynthesis mammography system, and its shares were down over 15 percent in trading after the bell.

The company said it would postpone its filing for its mammography system with U.S. health regulators, which was proposed for June 2009.

For the second quarter, the company posted a net loss of $2.30 billion, or $8.97 a share, compared with a net income of $56.0 million, or 22 cents a share, in the prior-year quarter.

The latest results included $2.34 billion of charges relating to the write-down of certain goodwill and intangible assets.

Revenue dropped 6.7 percent to $402.0 million, primarily due to year-over-year decline in sales of its Selenia systems.